Clinical Trial Update: Safety Study of BIIB033 in Subjects With Multiple Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 safety study of Opicinumab (BIIB033) in subjects with Relapsing-Remitting Multiple Sclerosis and Multiple Sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Opicinumab (opicinumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 1 | Status: COMPLETED